ArticleFrontiers in immunology2018

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

M Fevzi Ozkaynak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.